VIR BIOTECHNOLOGY INC (VIR) Stock Price & Overview
NASDAQ:VIR • US92764N1028
The current stock price of VIR is 9.88 USD. Today VIR is up by 0.82%. In the past month the price increased by 35.71%. In the past year, price increased by 38.18%.
VIR Key Statistics
- Market Cap
- 1.579B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.16
- Dividend Yield
- N/A
VIR Stock Performance
VIR Stock Chart
VIR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VIR. When comparing the yearly performance of all stocks, VIR is one of the better performing stocks in the market, outperforming 90.48% of all stocks.
VIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VIR. While VIR has a great health rating, there are worries on its profitability.
VIR Earnings
On February 23, 2026 VIR reported an EPS of -0.31 and a revenue of 64.07M. The company beat EPS expectations (37.56% surprise) and beat revenue expectations (173.63% surprise).
VIR Forecast & Estimates
14 analysts have analysed VIR and the average price target is 16.45 USD. This implies a price increase of 66.47% is expected in the next year compared to the current price of 9.88.
For the next year, analysts expect an EPS growth of 13.79% and a revenue growth -63.34% for VIR
VIR Groups
Sector & Classification
VIR Financial Highlights
Over the last trailing twelve months VIR reported a non-GAAP Earnings per Share(EPS) of -3.16. The EPS increased by 17.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.68% | ||
| ROE | -57.23% | ||
| Debt/Equity | 0 |
VIR Ownership
VIR Latest News, Press Relases and Analysis
VIR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.17B | ||
| AMGN | AMGEN INC | 16.45 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.72 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VIR
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Company Info
IPO: 2019-10-11
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158 US
CEO: George Scangos
Employees: 367
Phone: 14159064324
VIR BIOTECHNOLOGY INC / VIR FAQ
What does VIR do?
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
What is the stock price of VIR BIOTECHNOLOGY INC today?
The current stock price of VIR is 9.88 USD. The price increased by 0.82% in the last trading session.
What is the dividend status of VIR BIOTECHNOLOGY INC?
VIR does not pay a dividend.
What is the ChartMill technical and fundamental rating of VIR stock?
VIR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for VIR BIOTECHNOLOGY INC?
The Revenue of VIR BIOTECHNOLOGY INC (VIR) is expected to decline by -63.34% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for VIR BIOTECHNOLOGY INC?
VIR BIOTECHNOLOGY INC (VIR) currently has 367 employees.
Can you provide the market cap for VIR BIOTECHNOLOGY INC?
VIR BIOTECHNOLOGY INC (VIR) has a market capitalization of 1.58B USD. This makes VIR a Small Cap stock.